Camponeschi, A. et al. Human CD38 regulates B cell antigen receptor dynamic organization in normal and malignant B cells. J. Exp. Med. 219, e20220201 (2022).
Mayer, K. A. et al. A randomized phase 2 trial of felzartamab in antibody-mediated rejection. N. Engl. J. Med. 391, 122–132 (2024).
Hogan, K. A., Chini, C. C. S. & Chini, E. N. The multi-faceted ecto-enzyme CD38: roles in immunomodulation, cancer, aging, and metabolic diseases. Front. Immunol. 10, 1187 (2019).
Zeidler, J. D. et al. The CD38 glycohydrolase and the NAD sink: implications for pathological conditions. Am. J. Physiol. Cell Physiol. 322, C521–C545 (2022).
Boslett, J., Helal, M., Chini, E. & Zweier, J. L. Genetic deletion of CD38 confers post-ischemic myocardial protection through preserved pyridine nucleotides. J. Mol. Cell. Cardiol. 118, 81–94 (2018).
van de Donk, N. W. et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol. Rev. 270, 95–112 (2016).
Langer, P. et al. Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant. Cochrane Database Syst. Rev. 5, CD013595 (2024).
Loupy, A. & Lefaucheur, C. Antibody-mediated rejection of solid-organ allografts. N. Engl. J. Med. 379, 1150–1160 (2018).
Lamarthée, B. et al. Transcriptional and spatial profiling of the kidney allograft unravels a central role for FcyRIII+ innate immune cells in rejection. Nat. Commun. 14, 4359 (2023).
Floege, J. et al. Felzartamab (anti-CD38) in patients with IgA nephropathy — interim results from the IGNAZ study. Nephrol. Dial. Transplant. 39 (Suppl. 1), 425 (2024).
- The Renal Warrior Project. Join Now
- Source: https://www.nature.com/articles/s41581-024-00874-6